TR200002257T2 - Nükleer reseptör ligandları ve ligand bağlanma domainleri. - Google Patents

Nükleer reseptör ligandları ve ligand bağlanma domainleri.

Info

Publication number
TR200002257T2
TR200002257T2 TR2000/02257T TR200002257T TR200002257T2 TR 200002257 T2 TR200002257 T2 TR 200002257T2 TR 2000/02257 T TR2000/02257 T TR 2000/02257T TR 200002257 T TR200002257 T TR 200002257T TR 200002257 T2 TR200002257 T2 TR 200002257T2
Authority
TR
Turkey
Prior art keywords
nuclear receptor
ligand binding
binding domains
receptor ligands
nuclear
Prior art date
Application number
TR2000/02257T
Other languages
English (en)
Inventor
S. Scanlan Thomas
D. Baxter John
J. Fletterick Robert
L. Wagner Richard
J. Kushner Peter
W. Apriletti James
L. West Brian
K. Shiau Andrew
Original Assignee
The Regents Of The University Of California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Regents Of The University Of California filed Critical The Regents Of The University Of California
Publication of TR200002257T2 publication Critical patent/TR200002257T2/tr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/72—Receptors; Cell surface antigens; Cell surface determinants for hormones
    • C07K14/723—G protein coupled receptor, e.g. TSHR-thyrotropin-receptor, LH/hCG receptor, FSH receptor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/72—Receptors; Cell surface antigens; Cell surface determinants for hormones
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • G01N33/78—Thyroid gland hormones, e.g. T3, T4, TBH, TBG or their receptors
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B15/00—ICT specially adapted for analysing two-dimensional or three-dimensional molecular structures, e.g. structural or functional relations or structure alignment
    • G16B15/30—Drug targeting using structural data; Docking or binding prediction
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2299/00—Coordinates from 3D structures of peptides, e.g. proteins or enzymes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/72—Assays involving receptors, cell surface antigens or cell surface determinants for hormones
    • G01N2333/723—Steroid/thyroid hormone superfamily, e.g. GR, EcR, androgen receptor, oestrogen receptor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B15/00—ICT specially adapted for analysing two-dimensional or three-dimensional molecular structures, e.g. structural or functional relations or structure alignment

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Genetics & Genomics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Evolutionary Biology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Theoretical Computer Science (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Medical Informatics (AREA)

Abstract

Mevcut bulus, özellikle Tiroit reseptörü (bundan sonra ''TR'' olarak ifade edilecektir) gibi nükleer reseptörlerin 3 boyutlu yapisi esasinda nükleer reseptör sentetik ligandlarinin meydana getirilmesi için kompozisyon ve özellikle komputasyonel yöntemler gibi yöntemler temin eder. Ayrica temin edilenler, kristaller, nükleer reseptör sentetik ligandlari ve ilgili yöntemleri içerir.
TR2000/02257T 1997-11-26 1998-11-25 Nükleer reseptör ligandları ve ligand bağlanma domainleri. TR200002257T2 (tr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/980,115 US6266622B1 (en) 1995-12-13 1997-11-26 Nuclear receptor ligands and ligand binding domains

Publications (1)

Publication Number Publication Date
TR200002257T2 true TR200002257T2 (tr) 2000-12-21

Family

ID=25527367

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2000/02257T TR200002257T2 (tr) 1997-11-26 1998-11-25 Nükleer reseptör ligandları ve ligand bağlanma domainleri.

Country Status (11)

Country Link
US (2) US6266622B1 (tr)
EP (1) EP1034184A2 (tr)
JP (1) JP2001524489A (tr)
KR (1) KR20010032544A (tr)
CN (1) CN1290161A (tr)
AU (1) AU763452B2 (tr)
BR (1) BR9815061A (tr)
CA (1) CA2314096A1 (tr)
MX (1) MXPA00005241A (tr)
TR (1) TR200002257T2 (tr)
WO (1) WO1999026966A2 (tr)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6965850B2 (en) * 1998-03-30 2005-11-15 The Regents Of The University Of California Methods for modulating nuclear receptor coactivator binding
WO2000052050A2 (en) * 1999-03-01 2000-09-08 Karo Bio Ab Homology models of the glucocorticoid receptor
US20040033600A1 (en) 2001-03-21 2004-02-19 Palli Subba Reddy Ecdysone receptor-based inducible gene expression system
DE10024939A1 (de) 2000-05-19 2001-11-29 Bayer Ag Neue Diphenylmethanderivate für Arzneimittel
DE10038007A1 (de) 2000-08-04 2002-02-14 Bayer Ag Neue Amino-und Amido-Diphenylether für Arzneimittel
DE10046029A1 (de) 2000-09-18 2002-03-28 Bayer Ag Indazole
US8105825B2 (en) 2000-10-03 2012-01-31 Intrexon Corporation Multiple inducible gene regulation system
CA2433100A1 (en) 2000-12-27 2002-07-04 Helmut Haning Indole derivatives as ligands of thyroid receptors
WO2002066615A2 (en) * 2001-02-20 2002-08-29 Rheogene, Inc. Novel substitution mutant receptors and their use in a nuclear receptor-based inducible gene expression system
AU2002306550B2 (en) 2001-02-20 2007-10-25 Intrexon Corporation Novel substitution mutant receptors and their use in a nuclear receptor-based inducible gene expression system
ES2392508T3 (es) 2001-02-20 2012-12-11 Intrexon Corporation Receptores X retinoides quiméricos y su uso en un sistema inducible de expresión génica basado en receptores de ecdisona novedoso
US9493540B2 (en) 2001-02-20 2016-11-15 Intrexon Corporation Ecdysone receptor/invertebrate retinoid X receptor-based inducible gene expression system
US6777442B2 (en) 2001-03-12 2004-08-17 Bayer Aktiengesellschaft Diphenyl derivatives
US20030027315A1 (en) * 2001-09-24 2003-02-06 Ada Yonath Methods of growing crystals of free and antibiotic complexed large ribosomal subunits, and methods of rationally designing or identifying antibiotics using structure coordinate data derived from such crystals
WO2003027289A1 (en) 2001-09-26 2003-04-03 Rheo Gene Holdings, Inc. Leafhopper ecdysone receptor nucleic acids, polypeptides, and uses thereof
US7302347B2 (en) * 2002-12-10 2007-11-27 The Regents Of The University Of California Method for creating specific, high affinity nuclear receptor pharmaceuticals
WO2004052302A2 (en) * 2002-12-10 2004-06-24 The Regents Of The University Of California A method for creating specific, high affinity nuclear receptor pharmaceuticals
EP1587822A4 (en) * 2003-01-22 2006-04-19 Merck & Co Inc PEROXISOME-PROPERATOR-ACTIVATED RECEPTOR
GB0302446D0 (en) * 2003-02-03 2003-03-05 Imp College Innovations Ltd Screening for modulators of fat storage
EP1658036A2 (en) * 2003-08-26 2006-05-24 Board of Regents of the University of Texas System Estrogen receptor modulators and uses thereof
US20070087352A9 (en) * 2003-11-06 2007-04-19 Robert Fletterick Inhibitors for androgen antagonist refractory prostate cancer
JP2007512359A (ja) * 2003-11-19 2007-05-17 メタバシス・セラピューティクス・インコーポレイテッド 新規なリン含有甲状腺ホルモン様物質
US7935510B2 (en) 2004-04-30 2011-05-03 Intrexon Corporation Mutant receptors and their use in a nuclear receptor-based inducible gene expression system
US20060032110A1 (en) * 2004-08-16 2006-02-16 Keng-Ming Yang Trapping device
MX2007014502A (es) 2005-05-26 2008-02-07 Metabasis Therapeutics Inc Tiromimeticos para el tratamiento de enfermedades del higado graso.
WO2006128056A2 (en) * 2005-05-26 2006-11-30 Metabasis Therapeutics, Inc. Novel phosphinic acid-containing thyromimetics
CN101291640A (zh) * 2005-06-24 2008-10-22 托马斯·拉文 甲状腺素化合物用于人体烧伤和脂肪沉积的治疗
WO2010122980A1 (ja) 2009-04-20 2010-10-28 田辺三菱製薬株式会社 新規甲状腺ホルモンβ受容体作動薬
JP2020500199A (ja) 2016-11-21 2020-01-09 バイキング・セラピューティクス・インコーポレイテッド グリコーゲン蓄積症の治療方法
EA201992703A1 (ru) 2017-06-05 2020-04-15 Вайкинг Терапьютикс, Инк. Композиции для лечения фиброза
CN112135832A (zh) 2018-03-22 2020-12-25 维京治疗公司 化合物的晶型和制备化合物的晶型的方法

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3046306A (en) * 1959-06-24 1962-07-24 Warner Lambert Pharmaceutical Process of preparing triiodinated analogs of thyronine
US5061798A (en) * 1985-01-18 1991-10-29 Smith Kline & French Laboratories, Ltd. Benzyl pyridyl and pyridazinyl compounds
GB8501372D0 (en) * 1985-01-18 1985-02-20 Smith Kline French Lab Chemical compounds
US4741897A (en) * 1986-07-08 1988-05-03 Baxter Travenol Thyroxine analogs and reagents for thyroid hormone assays
US5071773A (en) * 1986-10-24 1991-12-10 The Salk Institute For Biological Studies Hormone receptor-related bioassays
US5171671A (en) * 1987-12-02 1992-12-15 The Salk Institute For Biological Studies Retinoic acid receptor composition
JP2708456B2 (ja) * 1988-03-31 1998-02-04 武田薬品工業株式会社 自動合成装置
US5025388A (en) * 1988-08-26 1991-06-18 Cramer Richard D Iii Comparative molecular field analysis (CoMFA)
US5438126A (en) * 1989-09-11 1995-08-01 Arch Development Corporation Human thyroid hormone receptor DNA
US5116828A (en) * 1989-10-26 1992-05-26 Nippon Zoki Pharmaceutical Co., Ltd. Pharmaceutical composition for treatment of osteoporosis
US5403925A (en) * 1989-12-13 1995-04-04 The United States Of America As Represented By The Department Of Health And Human Services Nucleic acids encoding mammalian H-2RIIBP or RXR.sub.β and uses thereof
JPH05503691A (ja) * 1989-12-29 1993-06-17 ユニバーシティ・テクノロジーズ・インターナショナル・インコーポレイテッド アゴニストおよびアンタゴニストを含む生物学的に活性なリガンドの３次構造モデルの設計方法およびアンギオテンシンに基づいた新規合成アンタゴニスト
US5284999A (en) * 1990-04-05 1994-02-08 Brigham And Women's Hospital DNA encoding a pituitary-specific thyroid hormone receptor
US5322933A (en) * 1992-05-07 1994-06-21 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Crystal structure of TGF-β-2
US5284971A (en) * 1992-07-16 1994-02-08 Syntex (U.S.A.) Inc. 4-(3-cyclohexyl-4-hydroxy or-methoxy phenylsulfonyl) 3,5 dibromo phenyl acetic thyromimetic cholesterol-lowering agents
US5466861A (en) * 1992-11-25 1995-11-14 Sri International Bridged bicyclic aromatic compounds and their use in modulating gene expression of retinoid receptors
US5463564A (en) * 1994-09-16 1995-10-31 3-Dimensional Pharmaceuticals, Inc. System and method of automatically generating chemical compounds with desired properties
EP0873361B1 (en) * 1995-12-13 2006-11-02 The Regents Of The University Of California Crystals of the ligand-binding domain of the thyroid hormone receptor complexed to a ligand
JP3345428B2 (ja) * 1996-08-20 2002-11-18 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 合成甲状腺ホルマン組成物を使用した眼の処置
US5883294A (en) * 1997-06-18 1999-03-16 The Regeants Of The University Of California Selective thyroid hormone analogs
US20040137518A1 (en) * 2002-01-31 2004-07-15 Lambert Millard Hurst CRYSTALLIZED PPARa LIGAND BINDING DOMAIN POLYPEPTIDE AND SCREENING METHODS EMPLOYING SAME

Also Published As

Publication number Publication date
WO1999026966A3 (en) 2000-01-20
CA2314096A1 (en) 1999-06-03
US6266622B1 (en) 2001-07-24
WO1999026966A2 (en) 1999-06-03
AU1799999A (en) 1999-06-15
KR20010032544A (ko) 2001-04-25
AU763452B2 (en) 2003-07-24
JP2001524489A (ja) 2001-12-04
EP1034184A2 (en) 2000-09-13
MXPA00005241A (es) 2002-08-06
BR9815061A (pt) 2001-11-20
CN1290161A (zh) 2001-04-04
US20070027215A1 (en) 2007-02-01

Similar Documents

Publication Publication Date Title
TR200002257T2 (tr) Nükleer reseptör ligandları ve ligand bağlanma domainleri.
EP0873361A4 (en) Nuclear receptor ligands and ligand binding domains
TR200101834T2 (tr) Yeni tiroid reseptör ligandları ve yöntem II
PT724456E (pt) Anticorpos contra cd4
DK0573545T3 (da) Monoklonale antistoffer mod receptor-inducerede bindingssteder
EP0584082A4 (en) Domains of extracellular region of human platelet derived growth factor receptor polypeptides
DK1066380T3 (da) Opløselig T-cellereceptor
IL143797A0 (en) Human monoclonal antibodies to cytotoxic t lymphocyte antigen 4
ITTO910545A1 (it) Tubazione integrata per carburante
CY1107821T1 (el) Πολυπεπτιδιο παραγοντα viii με ενεργοτητα παραγοντα viii:c
EP0167310A3 (en) Platinum co-ordination compounds
NO954320L (no) Lyosfærer omfattende gonadotropin
DE69939327D1 (de) Funktionelle antagonisten von hedgehog-aktivität
IT1164305B (it) Dispositivo di consegna e di svincolo per oggetti utilitari, come carrelli per bagagli
EP1021462A4 (en) TEST FOR CORE RECEPTOR LIGANDS USING FRET
TW272197B (tr)
ATE278422T1 (de) Ascomycin enthaltende topische zubereitungen
AU7657387A (en) Apoprotein b-100 specific monoclonal antibodies
DE69415154D1 (de) Chimäre selektine erhältlich durch domänenaustauch und ihre verwendungen
IT1196282B (it) Dispositivo di consegna e di svincolo di oggetti utilitari,come carrelli per bagagli
DK0457127T3 (da) Spermicidt belægningsmiddel
FR2668771B1 (fr) Acides nucleiques codant pour des polypeptides ayant une activite de recepteur dopaminergique humain et utilisation de ces polypeptides pour le criblage de substances actives sur ces polypeptides.
ATE328088T1 (de) Transketolase-verwandtes protein
Kizuka The synthesis and evaluation of radiolabeled bivalent beta-antagonist ligands as myocardial imaging agents
ES267998Y (es) "asiento mejorado para baneras".